News Detail
NEW DELHI, 12 DEC 2024: Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India.
Afrezza, a product created and manufactured by......
View Details
Source : Business Standard
Cipla
Afrezza
insulin inhalation
diabetes management
CDSCO approval
non-injectable insulin
type 1 diabetes
type 2 diabetes
rapid-acting insulin
India diabetes care
MannKind Corporation
insulin for diabetes
Related News
- Parliamentary Panel slams NPPA for 50% price hike (26-12-2024)
- Surat Police arrests individuals 'operating on people' without any medical degree (26-12-2024)
- DCA seizes 7 drugs over misleading claims; 60 seizures in 2024 (26-12-2024)
- J&K Issues Alert to stop use of Specific Bupivacaine Injection Batch after Doctors flag Severe Complications (26-12-2024)
- Smuggler arrested with 360 Narcotic cough syrup Bottles in Nuh (26-12-2024)
- Medicines 'Not For Sale' being sold at Medical Stores in Agra, 9 sacks and two bundles of injections seized (25-12-2024)
- AbbVie Healthcare India rejects allegations of the DoP (25-12-2024)
- DCA seizes overpriced Itraconazole capsules in Secunderabad (25-12-2024)
- Drug smuggler arrested with 160 Pentazocine in Faridabad (25-12-2024)
- Karnataka HC directs government not to act against firms producing nutraceuticals in drug-licensed units until next hearing (25-12-2024)